In view of the low sensitivity of Sokolow-Lyon voltage criteria in the assessment of electrocardiographic left ventricular hypertrophy (ECG LVH) in overweight subjects, we determined its clinical utility in 1840 lean and 3555 overweight subjects with hypertension. They were followed prospectively over an average of 11 years by the Department of Health and Social Security Hypertension Care Computer Project. LVH was determined at baseline using the Sokolow-Lyon criterion that is, the amplitude voltage SV1 þ (max RV5 or RV6) X3.5 mV. Overweight status was defined as body mass index (BMI) X25 kg m À2 . Prevalence of ECG LVH was 16% in lean and 12% in overweight women, 35 and 20% in lean and overweight men. For each 0.1 mV increase in ECG voltage as a continuous variable, the age and sex adjusted risk of stroke, coronary heart disease and cardiovascular disease (CVD) mortality increased significantly by 3.0, 1.5 and 1.8% in overweight subjects and by 2.8, 1.8 and 2.4% in lean subjects. After additional adjustments for smoking, blood glucose and serum cholesterol concentration in a subgroup of 654 lean and 1281 overweight subjects with complete information on these variables, an increasing voltage still significantly predicted stroke and CVD mortality in overweight subjects. The excess high risk of dying was evident especially in women with LVH in the highest BMI quartiles. When ECG detects LVH in overweight subjects, it is a good predictor of mortality despite the lower sensitivity in this group.
Introduction
The presence of left ventricular hypertrophy (LVH) in a hypertensive patient has been shown to be a predictor of cardiovascular sequelae whether determined by electrocardiogram (ECG LVH) or echocardiography (ECHO LVH). [1] [2] [3] Obesity has been shown to be associated with an increased anatomical LVH, usually an increased left ventricular mass estimated by ECHO. [4] [5] [6] [7] [8] This effect has been found to be at least additive to that of high blood pressure in the presence of hypertension. [5] [6] [7] [8] [9] [10] Echocardiography allows for a more precise diagnosis of anatomical LVH than the ECG. 1, 11 However, ECHO is less readily available than ECG and sometimes difficult to perform in the obese and the elderly. 7, 10 Therefore, the ECG has an important function in determining LVH. The commonly used Sokolow-Lyon ECG voltage criterion, that is, when the amplitude of SV1 þ (max RV5 or RV6) was equal to or above 3.5 mV, is very easy to use in the assessment of LVH. 12 The high specificity and lower cost makes the simple ECG method by Sokolow-Lyon criterion still the most frequently used, and in recent guidelines it is still on the list of routine tests to determine cardiac damage, together with the Cornell index. 11 The ability of different ECG criteria to identify ECHO LVH varies according to whether obesity is present or absent. [13] [14] [15] The decreased sensitivity of ECG criteria in obese subjects may be due to the accumulation of subcutaneous adipose tissue in the chest wall; [13] [14] [15] although, in women, the breast tissue appears to have only a small effect on ECG voltages. 16 Although Sokolow-Lyon criterion has a high specificity, its ability to reliably detect anatomical ECHO LVH compared with other ECG criteria has been shown to be relatively low, especially among obese subjects. The question has therefore been raised, whether this may limit its clinical utility in the presence of obesity. [13] [14] [15] Therefore, we examined the ability of the presence of LVH defined by the Sokolow-Lyon ECG criterion by body mass index (BMI) quartiles and the increasing voltage to predict stroke, coronary heart disease (CHD) and cardiovascular disease (CVD) mortality. This has not previously been evaluated separately in overweight and lean hypertensive subjects.
Materials and methods
The Department of Health and Social Security Hypertension Care Computer Project (DHCCP) is a multicentre, computer-based observational study, started in 1971, of patients being treated for hypertension in the United Kingdom. 17 The subjects were referred to specialized hospital hypertension clinics or seen in general practice with a diagnosis of hypertension. Ninety-five percent of patients entered the system on presentation to one of the hospital clinics (Hammersmith Hospital, London; King's College Hospital, London; John Radcliffe Hospital, Oxford; City Hospital, Birmingham; Aberdeen Royal Infirmary). The remaining 5% were recruited from the general practices involved in the study (Kentish Town, London, Harlow; Oxford and Norwich).
The present analytical database was created on 31 December 1986. Of the 10 186 subjects referred for hypertension and recruited up to that date, 5798 subjects had height and weight measured and ECG recorded at entry. Information on the presence or absence of ECG LVH, age, sex, systolic blood pressure (SBP), race, BMI, previous myocardial infarction and cerebrovascular accident and whether or not the subjects were on antihypertensive drug treatment before presentation (N ¼ 2128, the treatment group) was available in 2690 women and 2705 men. These variables in the analyses were selected from variables present in the vast majority of patients. Each of those variables was a significant predictor in a stepwise model for at least one of the fatal end points. Information on smoking was available in 2354 women and 2362 men. Smokers were those who currently smoked or who had smoked in the past. The blood glucose concentrations were measured in 1642 women and in 1629 men, serum cholesterol concentration in 1567 women and 1627 men. Blood glucose measurements at baseline were not necessarily taken in the fasting state and they were not formally standardized, although performed in laboratories linked to the United Kingdom quality assurance scheme. The assessors were trained by clinical doctors familiar with ECGs and they evaluated the standard 12-lead resting ECGs at presentation to the clinics. ECG-LVH was determined using the Sokolow-Lyon voltage criterion. All ECGs were recorded at 1 mV cm
À1
calibration. Blood pressure measurements were not formally standardized but were performed by experienced observers. Most observers used phase V Korotkoff as diastolic blood pressure (DBP). SBP and DBP measurements were taken as the measurement closest to the date of presentation or during the first follow-up year. BMI was calculated as weight (kg)/ height squared (m 2 ). In agreement with the National Institutes of Health Clinical Guidelines, 18 overweight was defined as a BMI at least 25 kg m À2 . Data are presented by BMI groups for lean (BMIo25 kg m À2 ) and for combined overweight and obese subjects. In this paper, we refer to the group of subjects with BMIX25 kg m À2 as overweight. All patients were registered with the office of National Statistics for England and Wales, and the Registrar General for Scotland, which provided copies of the death certificates. Codes 4300-4389 were classified as stroke deaths, codes 4100-4149 as CHD deaths and codes 3900-4589 and 7950-7959 as CVD deaths (International Classification of Diseases, eighth revision).
Statistical methods
The differences in mean values and standard deviations were compared using Student's t-test. Comparisons between proportions were performed using the w 2 test for independent groups (Table 1 ). In the categorical analysis (Table 2) , we assessed the relative risk of stroke, CHD and CVD mortality in women and men with LVH compared with those without LVH, according to quartiles of BMI. We adjusted first for age and then in the multivariate model for age, SBP, weight, race, history of myocardial infarction and cerebrovascular accident and treatment status before presentation (treated ¼ 1, À2 . Additionally, linear trends for the relative risk of stroke CHD and CVD associated with the presence of LVH over BMI quartiles were determined. This was calculated using Wald w 2 test. The interactions between sex and increasing voltage on the risk of mortality were not statistically significant. Therefore, the relative risks and the 95% confidence limits for mortality associated with a 0.1 mV increase in baseline ECG voltage were calculated in lean (N ¼ 1840) and overweight (N ¼ 3555) women and men combined. The relative risks of mortality were adjusted first for age and sex, then for variables in the model. In this clinical series of hypertensive subjects, complete information on all important cardiovascular risk factors may not have been present. Finally, we adjusted for variables in the model and additionally for smoking, serum cholesterol and blood glucose concentration in a subgroup of 654 lean and 1281 overweight subjects with complete information on these variables. Weight, race and treatment status were not signifi-cant predictors of mortality in the stepwise model and they were excluded from analyses.
Multivariate analyses were performed by using the Cox proportional hazards model. 19 Statistical analyses were performed using the SAS statistical programs (The SAS Institute Inc., Cary, NC, USA).
Results
In this hypertensive DHCCP population, there were 1671 (62%) overweight women and 1884 (70%) overweight men. ECG LVH defined using the Sokolow-Lyon criterion was identified in 168 (16%) of lean and in 200 (12%) of overweight women ( Table 1 ). The corresponding numbers were 290 (35%) and 385 (20%) for lean and overweight men. Compared with subjects without LVH, those with LVH had significantly higher average SBP and DBP, black race was more prevalent and the BMI was lower in both the lean and overweight subjects. Overweight subjects with LVH were significantly older than those without LVH. The prevalence of a history of previous myocardial infarction or cerebrovascular accident was significantly higher among overweight women and lean men with LVH. Antihypertensive drug treatment before presentation was significantly more prevalent and average serum cholesterol concentration was lower among overweight men with LVH. Lean men with LVH at baseline had a lower mean blood glucose concentration and they were more often a smoker than men without LVH.
During the mean follow-up time of 11.1 years, a total of 215 lean and 444 overweight women and 244 lean and 598 overweight men died from stroke, CHD or CVD. In women, the higher the BMI quartile, the higher were the risk estimates of stroke mortality associated with the presence of LVH (P ¼ 0.058 for trend) ( Table 2 ). This was confirmed after adjustments for age, SBP, weight, race, history of myocardial infarction and cerebrovascular accident and treatment status before presentation (P ¼ 0.042 for trend) in the model. In the two highest quartiles in women, the 2.6-and 4.1-fold age adjusted risk for stroke mortality and 1.8-and 2.4-fold risk for CVD mortality were statistically significant. In men, the association between the presence of LVH and risk mortality was not statistically significant in any of quartiles. After adjustment for age and sex, each 0.1 mV increment in the ECG voltage was associated with a 2.8% increase (P ¼ 0.006) in the risk of stroke mortality among lean subjects and with a 3.0% increase (Po0.001) among overweight subjects (Table 3 ). The corresponding results for CHD mortality were 1.8% (P ¼ 0.064) and 1.5% (0.010) and for CVD mortality 2.4% (Po0.001) and 1.8% (Po0.001) among lean and overweight subjects, respectively. After adjustments for variables in the model, the risk of stroke and CVD mortality in overweight subjects remained statistically significant. In lean subjects, only a 1.6% increase in the CVD mortality as a continuous variable remained significant.
An analyses incorporating information on smoking, serum cholesterol and blood glucose concentration could only be performed in 36% of subjects. The prevalences of LVH in this group were very similar to the prevalences presented in Table 1 . After full adjustments for variables in the subgroup with complete baseline information, each 0.1 mV increment in the ECG voltage in overweight subjects was associated with a 3.9% (P ¼ 0.005) increase in the risk of fatal stroke and a 2.0% (P ¼ 0.007) increase in the risk of fatal CVD, whereas the 1.7% increase in the risk of CHD mortality was not statistically significant. An increasing ECG voltage did not predict significantly the risk of mortality among lean subjects (data not shown).
Discussion
The principal finding in this study of a large sample of hypertensive patients was that in overweight subjects, although the prevalence of ECG LVH was reduced, an increase in ECG voltage was a strong and independent predictor, especially of stroke and CVD mortality. The detrimental prognostic effect of the LVH was present, in particular, in the highest BMI quartiles of women. Increasing voltage predicted CVD mortality among lean subjects, but in subgroup analyses among subjects with complete information on baseline variables this association was lacking.
Interestingly, among women LVH ECG was strongly associated with stroke and CVD mortality in higher BMI quartiles. We have discussed stroke mortality associated with LVH without reference to the level of BMI. 20 Obesity has been found to be associated with a greater increase of left ventricular muscle mass in women than men, especially in the presence of hypertension. 5, 6, 21 In the Framingham Heart Study, 22 after adjusting for BMI and other risk factors, glucose intolerance was observed to be related to the left ventricular mass more strongly in women than in men, suggesting that the association between obesity and the left ventricular mass was related to the presence of insulin resistance in women. Statistical interactions between increasing voltage and BMI group or gender on the risk of mortality were not significant, thus formally this study has not proven any difference in the prognostic effect of LVH between women and men or between lean and overweight subjects. However, it is noteworthy that in the linear trend for stroke over the increasing BMI quartiles was significant among women. This may reflect the superiority of the Sokolow-Lyon criteria as a predictor among overweight women Both hypertension and ECG LVH have been shown to predict the development of atrial fibrillation, a major independent risk for stroke. 23 In a recent meta-analysis, obesity increased the risk of developing atrial fibrillation by 49% based in population-based cohorts. The risk of incident atrial fibrillation was similar in both obese women and men, with somewhat larger risk estimates for women. 24 In our study, information on the presence of atrial fibrillation was not available at baseline or during follow-up, thus its function in mortality remains unclear.
Using the single-partition value for men and women in our study may have overestimated the prevalence of LVH, in particular, in men. The use of gender-specific partition values for Sokolow-Lyon ECG criteria of LVH has been proposed by Alfakih et al. 25 to detect subjects with elevated left ventricular mass. Therefore, we additionally assessed the risk associated with the presence of LVH using these new gender-specific partition values for SokolowLyon criteria for LVH (X3.4 mV for women and X3.8 mV for men). In lean and overweight subjects in the Table 3 , the adjusted risk estimates using new partition values remained similar to using the 3.5 mV criterion for LVH. However, the risk estimates of stroke and CHD mortality associated with the presence of LVH among overweight subjects in the subgroup analyses were slightly lower and they were no longer significant. This finding suggests that the old Sokolow-Lyon criteria may not be inferior to the gender-specific criteria in identifying the risk. In this study, it was not possible to determine any effect of antihypertensive drug treatment on the risks of mortality. Diuretic treatment was significantly more prevalent in women without LVH than in men without LVH, 45.8 and 40.7%, respectively (Po0.001). On the other hand, b-blockers were less prevalent in women with LVH than in men with LVH, 49.0 and 56.5%, respectively (P ¼ 0.024). The relative risk of mortality was additionally adjusted for diuretic or for b-blocker treatment. In both analyses, the relative risks remained very similar to the risk estimates in Tables 2 and 3 . A differential response to antihypertensive treatment according to BMI was observed in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) 26 study and might be a possible partial explanation for some of our data. However, in the 1980s and 1990s, the treatment and control of hypertension has been far from the recommended goals, 27 according to the recent guidelines.
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Strengths and limitations
The main strength of our study is the high number of hypertensive subjects with information on the presence or absence of ECG LVH, as defined by the commonly used Sokolow-Lyon criterion. Blood pressure was often measured only once. However, patients were referred with hypertension to the study and the single blood pressure measurement might not overestimate the patient's usual blood pressure level, as these subjects will have been accustomed to blood pressure recording. Also, ECG LVH at baseline was not always measured at the same time as blood pressure, the latter may have been determined some time previously or during the first year of follow-up. Since most patients referred with hypertension between 1971 and 1986 presented with elevated DBP, this study clearly was biased towards diastolic hypertension. Also, the prevalence of ECG LVH by Sokolow-Lyon criteria was high compared with more recent studies, 28, 29 which may indicate an increase in the hypertension awareness and improved control during the last decades. Long-term mortality data were obtained from death certificates. These are known for their potential inaccuracies, but the diagnosis of stroke is often robust. Not all subjects had information on smoking, serum cholesterol and blood glucose concentration measurements. It is not excluded that the missing information on baseline variables might have generated the potential for selection bias. After full adjustments, in a subgroup of patients with complete information on significant predictors, increasing voltage was associated with an increase in the relative risk of stroke, CHD and CVD mortality in overweight subjects. This finding supported those in Table 3 . Previous Q-wave myocardial infarction may interfere with the height of ECG voltage. In this study, a diagnosis of previous myocardial infarction at presentation was made in 68 lean and in 162 overweight subjects. The prevalence of LVH in these was 38% for overweight and 20% for lean subjects (the corresponding proportions were 25 and 16% for all lean and overweight subjects). For each 1 mV increase in the voltage, the adjusted risk of stroke, CHD and CVD among overweight subjects with previous myocardial infarction increased 4.7% (P ¼ 0.037), 2.1% (P ¼ 0.130) and 2.5% (P ¼ 0.029), respectively. Thus, it is not likely that a Q-wave infarction would conceal the presence of LVH.
In this study, the prevalence of LVH by SokolowLyon criteria was lower in overweight than in lean subjects presumable due to a lower sensitivity of the Sokolow-Lyon criterion in the overweight subjects. The absence of ECG LVH by the Sokolow-Lyon criterion does not exclude the presence of anatomical LVH. [13] [14] [15] 30 Therefore, ECG test possibly cannot be used only as a surrogate of ECHO in detecting or excluding anatomical LVH. 31 ECHO LVH and ECG LVH have been shown to predict mortality independently of each other, 32 and anatomical ECHO LVH and electrical ECG LVH might reflect a different pathogenesis. 1, [30] [31] [32] The present data support the clinical utility of ECG LVH positivity determined using Sokolow-Lyon voltage criteria and that it should be used in addition to other methods for assessing the CVD risk. If ECG is detecting LVH in overweight subjects, it is a good predictor of mortality.
